ClinicalTrials.gg
CompletedNCT02970929Updated Jul 5, 2024Results posted

An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia

A Phase 2 interventional study of SEP-363856 in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 30 sites in 5 countries. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-07-05.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
157
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing SEP-363856 in Schizophrenia — 1 open to participants now, 2 under way, 2 of them phase 3. SEP-363856 · Schizophrenia.

Enrollment
7th of 23
157 · median 83
Started
2017
with 1 other
Phase 2
2 of 23
none open now
Registered
4th of 23
by date
Lead sponsor
18 of 23
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 23 studies testing SEP-363856 in Schizophrenia, this one is the 7th largest by enrollment, is one of 2 that started in 2017, is one of 2 in phase 2, and was the 4th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 23 studies testing SEP-363856 in Schizophrenia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About SEP-363856

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing SEP-363856 in Schizophrenia, or all of them as a file.
02

Study summary

An extension study of safety and tolerability of SEP-363856 in adult subjects with schizophrenia

Read the detailed description

This is a 26 week, multiregional, open-label extension study designed to evaluate the long-term safety and tolerability of SEP-363856 for the treatment of subjects with schizophrenia who have completed the 4 week double-blind treatment phase of Study SEP361-201 (NCT02969382) Subjects received open-label SEP-363856 50 mg/day from Day 1 through Day 3, and then received flexible dosing of SEP-363856 (25, 50, or 75 mg/day) for the rest of the trial.

No statistical hypothesis tests will be performed.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject must give written and privacy authorization prior to participation in the study and able to comply with the protocol, in the opinion of the investigator.

  • Subject has completed Study SEP361 201 through Week 4
  • Subject has not taken any medication other than the study drug for the purpose of controlling schizophrenia symptoms during Study SEP361 201.
  • Female subject must have a negative urine pregnancy test at Visit 7 of Study SEP361 201; females who are (defined as at least 12 months of spontaneous amenorrhea) and those who have undergone hysterectomy or bilateral oophorectomy will be exempted from the pregnancy test.
  • Male subjects with female partner(s) of must agree to avoid fathering a child and use acceptable methods of from screening until at least 30 days after the last study drug administration

Exclusion criteria

Exclusion Criteria:

  • Subject answers "yes" to "suicidal ideation" Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS assessment at Visit 7 of Study SEP361 201. Subjects who answer "yes" to this question must be referred to the Investigator for follow up evaluation.
  • Subject has a abnormality including physical examination, vital signs, , or laboratory test at Visit 7 of Study SEP361 201 that the investigator in consultation with the medical monitor considers to be inappropriate to allow participation in the study.
  • Subject has a positive urine drug screen (UDS) or breath alcohol test at Visit 7 of Study SEP361 201.
  • Subject is pregnant or lactating.
  • Subject is at high risk of non-compliance in the Investigator's opinion.
  • Subject is in the opinion of the Investigator, unsuitable in any other way to participate in this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
157 participants (actual)

Study arms

  • Experimental
    SEP-363856

    SEP-363856 capsule (25 mg, 50 mg, or 75 mg) once daily

    Drug: SEP-363856

Interventions

  • One SEP-363856 capsule (25 mg, 50 mg or 75 mg (flex)) daily for 26 weeks

06

What researchers measure

Primary outcomes

  1. The Incidence of Overall Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation

    Number of Participants with overall Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) leading to discontinuation

    Time frame: From first dose of study drug to last study visit (27 weeks)

Secondary outcomes

  1. Frequency of Suicidal Ideation (SI) and Suicidal Behavior (SB) Using the Columbia - Suicide Severity Rating Scale (C-SSRS)

    Number of participants with suicidal ideation (SI) and suicidal behavior (SB) using the Columbia - Suicide Severity Rating Scale (C-SSRS). The C-SSRS is a tool designed to systematically assess and track suicidal behavior and suicidal ideation for life time, one month prior to the screening visit for suicidal ideation and 6 months prior to the screening visit for suicidal behavior, and throughout the study. The strength of this suicide classification system is in its ability to comprehensively identify suicidal events while limiting the over-identification of suicidal behavior.

    Time frame: Overall post Open-label Baseline treatment period (26 weeks)

  2. Severity of Suicidal Ideation (SI) and Suicidal Behavior (SB) Using the Columbia - Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a tool designed to systematically assess and track suicidal behavior and suicidal ideation for life time, one month prior to the screening visit for suicidal ideation and 6 months prior to the screening visit for suicidal behavior, and throughout the study. The strength of this suicide classification system is in its ability to comprehensively identify suicidal events while limiting the over-identification of suicidal behavior.

    Time frame: Overall post Open-label Baseline treatment period (26 weeks)

  3. Time to Relapse During the 26-week Open-label Treatment Period for Subjects Who Demonstrated a Clinical Response to 4 Weeks of Treatment With SEP-363856

    Relapse is defined as the earliest occurrence of any of the following: - An increase in PANSS total score by ≥ 30% from the PANSS total score at clinical response and a CGI-S score ≥ 3; - Re-hospitalization for worsening of psychosis; - Emergence of suicidality, homicidality, and/or risk of harm to self or others.

    Time frame: From the time of clinical response to relapse or censor (one day after the last study drug dose)

  4. Rate of Relapse During the 26-week Open-label Treatment Period for Subjects Who Demonstrated a Clinical Response to 4 Weeks of Treatment With SEP-363856

    Relapse is defined as the earliest occurrence of any of the following: - An increase in PANSS total score by ≥ 30% from the PANSS total score at clinical response and a CGI-S score ≥ 3; - Re-hospitalization for worsening of psychosis; - Emergence of suicidality, homicidality, and/or risk of harm to self or others.

    Time frame: From the time of clinical response to relapse or censor (one day after the last study drug dose)

  5. Changes From Double-blind Baseline of Study SEP361-201 and Open-label Baseline of Study SEP361-202 in Positive and Negative Syndrome Scale (PANSS) Total Score and Subscale Scores (Positive, Negative, and General Psychopathology)

    PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210.

    Time frame: Double-blind Baseline (DB BLN), Open-label Baseline (OL BLN), Week 26 (Wk 26)

  6. Change From Double-blind Baseline of Study SEP361-201 and Open-label Baseline of Study SEP361-202 in Clinical Global Impression - Severity (CGI-S) Score

    The CGI-S is a single-item clinician-rated assessment of the subject's current illness state on a 7-point scale (score range: 1-7), where a higher score is associated with greater illness severity.

    Time frame: Double-blind (DB) Baseline, Open-label (OL) Baseline, Week 26

  7. Change From Double-blind Baseline of Study SEP361-201 and Open-label Baseline of Study SEP361-202 in Brief Negative Symptom Scale (BNSS) Total Score

    The BNSS is a rating scale to measure the current level of severity of negative symptoms in schizophrenia and schizoaffective disorder. The measure is comprised of 13 individual items organized in 6 subscales. The 13 individual items provide a composite total score (ranging from 0 to 78). Each of the items are scored on a Likert-type 7-point scale from 0 - 6, where values of 0 indicates symptom is absent and a value of 6 means the symptom is a severe form.

    Time frame: Double-blind (DB) Baseline, Open-label (OL) Baseline, Week 26

  8. Change From Double-blind Baseline of Study SEP361-201 and Open-label Baseline of Study SEP361-202 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    The MADRS is a clinician-rated assessment of the subject's level of depression. The measure contains 10 items that measure apparent and reported sadness, inner tension, reduced sleep and appetite, difficulty concentrating, lassitude, inability to feel, and pessimistic and suicidal thoughts. Each item is scored in a range of 0 to 6 points, with higher scores indicating increased depressive symptoms. Total score will be equal to the sum of the 10 items (range between 0 and 60).

    Time frame: Double-blind (DB) Baseline, Open-label (OL) Baseline, Week 26

  9. Proportion of Subjects Who Achieved a Response, Defined as a 20% or Greater Improvement in Positive and Negative Syndrome Scale (PANSS) Total Score From Double-blind Baseline of Study SEP361-201

    PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210.

    Time frame: Week 26

07

Results

Posted Feb 9, 2022

Participant flow

Participant flow — Overall Study
MilestoneSEP-363856
Started157
Subjects who received study medication156
Completed105
Not completed52
Withdrew: Adverse event18
Withdrew: Lack of efficacy8
Withdrew: Non-compliance with study drug1
Withdrew: Investigator considers subject clinically unstable, not appropriate for discharge to an outpatient1
Withdrew: Sponsor request that subject be withdrawn due to positive drug results and for the subject's safety1
Withdrew: Lost to followup6
Withdrew: Moved out of state1
Withdrew: Withdrawal by subject16

Outcome measures

PrimaryThe Incidence of Overall Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation

Number of Participants with overall Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) leading to discontinuation

Time frame:
From first dose of study drug to last study visit (27 weeks)
Reported as:
Count of participants · Participants
The Incidence of Overall Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation
ParticipantsSEP-363856
Overall Adverse Events (AEs)88
Serious Adverse Events (SAEs)15
Adverse Events leading to discontinuation from study18
Adverse Events leading to discontinuation of study drug18
SecondaryFrequency of Suicidal Ideation (SI) and Suicidal Behavior (SB) Using the Columbia - Suicide Severity Rating Scale (C-SSRS)

Number of participants with suicidal ideation (SI) and suicidal behavior (SB) using the Columbia - Suicide Severity Rating Scale (C-SSRS). The C-SSRS is a tool designed to systematically assess and track suicidal behavior and suicidal ideation for life time, one month prior to the screening visit for suicidal ideation and 6 months prior to the screening visit for suicidal behavior, and throughout the study. The strength of this suicide classification system is in its ability to comprehensively identify suicidal events while limiting the over-identification of suicidal behavior.

Time frame:
Overall post Open-label Baseline treatment period (26 weeks)
Reported as:
Count of participants · Participants
Frequency of Suicidal Ideation (SI) and Suicidal Behavior (SB) Using the Columbia - Suicide Severity Rating Scale (C-SSRS)
ParticipantsSEP-363856
Any suicidal ideation3
Any suicidal behavior1
Any suicidality3
SecondarySeverity of Suicidal Ideation (SI) and Suicidal Behavior (SB) Using the Columbia - Suicide Severity Rating Scale (C-SSRS)

The C-SSRS is a tool designed to systematically assess and track suicidal behavior and suicidal ideation for life time, one month prior to the screening visit for suicidal ideation and 6 months prior to the screening visit for suicidal behavior, and throughout the study. The strength of this suicide classification system is in its ability to comprehensively identify suicidal events while limiting the over-identification of suicidal behavior.

Time frame:
Overall post Open-label Baseline treatment period (26 weeks)
Reported as:
Count of participants · Participants
Severity of Suicidal Ideation (SI) and Suicidal Behavior (SB) Using the Columbia - Suicide Severity Rating Scale (C-SSRS)
ParticipantsSEP-363856
SI: Wish to be dead2
SI: Non-specific active suicidal thoughts2
SI: Any methods (not plan) without intent to act0
SI: Some intent to act, without specific plan0
SI: Specific plan and intent0
SB: Preparatory acts or behavior0
SB: Aborted attempt1
SB: Interrupted attempt0
SB: Actual attempt (non-fatal)0
SB: Completed suicide0
SecondaryTime to Relapse During the 26-week Open-label Treatment Period for Subjects Who Demonstrated a Clinical Response to 4 Weeks of Treatment With SEP-363856

Relapse is defined as the earliest occurrence of any of the following: - An increase in PANSS total score by ≥ 30% from the PANSS total score at clinical response and a CGI-S score ≥ 3; - Re-hospitalization for worsening of psychosis; - Emergence of suicidality, homicidality, and/or risk of harm to self or others.

Time frame:
From the time of clinical response to relapse or censor (one day after the last study drug dose)
Reported as:
Median · Days
Time to Relapse During the 26-week Open-label Treatment Period for Subjects Who Demonstrated a Clinical Response to 4 Weeks of Treatment With SEP-363856
DaysPBO-SEPSEP-SEP
Time to Relapse During the 26-week Open-label Treatment Period for Subjects Who Demonstrated a Clinical Response to 4 Weeks of Treatment With SEP-363856NA (NA to NA)NA (NA to NA)
SecondaryRate of Relapse During the 26-week Open-label Treatment Period for Subjects Who Demonstrated a Clinical Response to 4 Weeks of Treatment With SEP-363856

Relapse is defined as the earliest occurrence of any of the following: - An increase in PANSS total score by ≥ 30% from the PANSS total score at clinical response and a CGI-S score ≥ 3; - Re-hospitalization for worsening of psychosis; - Emergence of suicidality, homicidality, and/or risk of harm to self or others.

Time frame:
From the time of clinical response to relapse or censor (one day after the last study drug dose)
Reported as:
Count of participants · Participants
Rate of Relapse During the 26-week Open-label Treatment Period for Subjects Who Demonstrated a Clinical Response to 4 Weeks of Treatment With SEP-363856
ParticipantsPBO-SEPSEP-SEP
Rate of Relapse During the 26-week Open-label Treatment Period for Subjects Who Demonstrated a Clinical Response to 4 Weeks of Treatment With SEP-3638561211
SecondaryChanges From Double-blind Baseline of Study SEP361-201 and Open-label Baseline of Study SEP361-202 in Positive and Negative Syndrome Scale (PANSS) Total Score and Subscale Scores (Positive, Negative, and General Psychopathology)

PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210.

Time frame:
Double-blind Baseline (DB BLN), Open-label Baseline (OL BLN), Week 26 (Wk 26)
Reported as:
Mean · Units on a scale
Changes From Double-blind Baseline of Study SEP361-201 and Open-label Baseline of Study SEP361-202 in Positive and Negative Syndrome Scale (PANSS) Total Score and Subscale Scores (Positive, Negative, and General Psychopathology)
Units on a scaleSEP-363856
Total Score: DB BLN Observed101.5 ± 7.99
Total Score: OL BLN Observed83.1 ± 15.03
Total Score: Wk 26 Observed59.3 ± 12.45
Total Score: Chg from DB BLN at Wk 26-41.8 ± 13.98
Total Score: Chg from OL BLN at Wk 26-22.6 ± 15.48
Positive SS: DB BLN Observed25.7 ± 3.22
Positive SS: OL BLN Observed19.8 ± 4.96
Positive SS: Wk 26 Observed12.2 ± 3.72
Positive SS: Chg from DB BLN at Wk 26-13.5 ± 4.75
Positive SS: Chg from OL BLN at Wk 26-7.3 ± 5.37
Negative SS: DB BLN Observed25.4 ± 4.03
Negative SS: OL BLN Observed22.3 ± 4.38
Negative SS: Wk 26 Observed17.2 ± 4.10
Negative SS: Chg from DB BLN at Wk 26-8.4 ± 4.48
Negative SS: Chg from OL BLN at Wk 26-5.2 ± 4.20
Gen-Psychopathology SS: DB BLN Observed50.4 ± 5.01
Gen-Psychopathology SS: OL BLN Observed41.1 ± 7.93
Gen-Psychopathology SS: Wk 26 Observed30.0 ± 6.77
Gen-Psychopathology SS: Chg from DB BLN at Wk 26-19.9 ± 7.86
Gen-Psychopathology SS: Chg from OL BLN at Wk 26-10.2 ± 8.31
SecondaryChange From Double-blind Baseline of Study SEP361-201 and Open-label Baseline of Study SEP361-202 in Clinical Global Impression - Severity (CGI-S) Score

The CGI-S is a single-item clinician-rated assessment of the subject's current illness state on a 7-point scale (score range: 1-7), where a higher score is associated with greater illness severity.

Time frame:
Double-blind (DB) Baseline, Open-label (OL) Baseline, Week 26
Reported as:
Mean · Units on a scale
Change From Double-blind Baseline of Study SEP361-201 and Open-label Baseline of Study SEP361-202 in Clinical Global Impression - Severity (CGI-S) Score
Units on a scaleSEP-363856
CGI-S Score: DB Baseline Observed5.0 ± 0.42
CGI-S Score: OL Baseline Observed4.0 ± 0.84
CGI-S Score: Week 26 Observed3.0 ± 0.74
CGI-S Score: Change from DB Baseline at Week 26-2.0 ± 0.82
CGI-S Score: Change from OL Baseline at Week 26-1.0 ± 0.91
SecondaryChange From Double-blind Baseline of Study SEP361-201 and Open-label Baseline of Study SEP361-202 in Brief Negative Symptom Scale (BNSS) Total Score

The BNSS is a rating scale to measure the current level of severity of negative symptoms in schizophrenia and schizoaffective disorder. The measure is comprised of 13 individual items organized in 6 subscales. The 13 individual items provide a composite total score (ranging from 0 to 78). Each of the items are scored on a Likert-type 7-point scale from 0 - 6, where values of 0 indicates symptom is absent and a value of 6 means the symptom is a severe form.

Time frame:
Double-blind (DB) Baseline, Open-label (OL) Baseline, Week 26
Reported as:
Mean · Units on a scale
Change From Double-blind Baseline of Study SEP361-201 and Open-label Baseline of Study SEP361-202 in Brief Negative Symptom Scale (BNSS) Total Score
Units on a scaleSEP-363856
Total Score: DB Baseline Observed38.4 ± 11.94
Total Score: OL Baseline Observed33.0 ± 11.41
Total Score: Week 26 Observed22.5 ± 11.83
Total Score: Change from DB Baseline at Week 26-16.8 ± 12.42
Total Score: Change from OL Baseline at Week 26-11.3 ± 9.69
SecondaryChange From Double-blind Baseline of Study SEP361-201 and Open-label Baseline of Study SEP361-202 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

The MADRS is a clinician-rated assessment of the subject's level of depression. The measure contains 10 items that measure apparent and reported sadness, inner tension, reduced sleep and appetite, difficulty concentrating, lassitude, inability to feel, and pessimistic and suicidal thoughts. Each item is scored in a range of 0 to 6 points, with higher scores indicating increased depressive symptoms. Total score will be equal to the sum of the 10 items (range between 0 and 60).

Time frame:
Double-blind (DB) Baseline, Open-label (OL) Baseline, Week 26
Reported as:
Mean · Units on a scale
Change From Double-blind Baseline of Study SEP361-201 and Open-label Baseline of Study SEP361-202 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Units on a scaleSEP-363856
Total Score: DB Baseline Observed12.6 ± 7.25
Total Score: OL Baseline Observed9.2 ± 6.33
Total Score: Week 26 Observed4.4 ± 4.72
Total Score: Change from DB Baseline at Week 26-8.1 ± 6.44
Total Score: Change from OL Baseline at Week 26-4.5 ± 5.28
SecondaryProportion of Subjects Who Achieved a Response, Defined as a 20% or Greater Improvement in Positive and Negative Syndrome Scale (PANSS) Total Score From Double-blind Baseline of Study SEP361-201

PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Proportion of Subjects Who Achieved a Response, Defined as a 20% or Greater Improvement in Positive and Negative Syndrome Scale (PANSS) Total Score From Double-blind Baseline of Study SEP361-201
ParticipantsPBO-SEPSEP-SEP
Proportion of Subjects Who Achieved a Response, Defined as a 20% or Greater Improvement in Positive and Negative Syndrome Scale (PANSS) Total Score From Double-blind Baseline of Study SEP361-2015249

Adverse events

Collected over From first dose of study drug to last study visit (27 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SEP-3638560/156 (0%)15/156 (9.6%)39/156 (25%)
Most frequent serious events
Most frequent serious events
EventSEP-363856
SchizophreniaPsychiatric disorders11/156
Acute psychosisPsychiatric disorders1/156
DepressionPsychiatric disorders1/156
Psychotic disorderPsychiatric disorders1/156
Suicidal ideationPsychiatric disorders1/156
Uterine haemorrhageReproductive system and breast disorders1/156
Most frequent other events
Most frequent other events
EventSEP-363856
HeadacheNervous system disorders18/156
InsomniaPsychiatric disorders13/156
SchizophreniaPsychiatric disorders10/156
AnxietyPsychiatric disorders8/156

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SEP-363856
<=18 years2
Between 18 and 65 years154
>=65 years0
Age, Continuous
Age, Continuous(Years)SEP-363856
Mean30.2 ± 6.03
Sex: Female, Male
Sex: Female, Male(Participants)SEP-363856
Female54
Male102
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SEP-363856
Hispanic or Latino5
Not Hispanic or Latino151
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SEP-363856
American Indian or Alaska Native4
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American15
White136
More than one race1
Unknown or Not Reported0
Age, Customized
Age, Customized(Participants)SEP-363856
>=18 - <25 years38
>=25 - <=40 years118
Country
Country(Participants)SEP-363856
Hungary8
Romania6
Russia68
Ukraine54
United States20
Double-blind Baseline BMI (Body Mass Index) Group
Double-blind Baseline BMI (Body Mass Index) Group(Participants)SEP-363856
<18.5 kg/m^22
>=18.5 - <25.0 kg/m^280
>=25.0 - <30.0 kg/m^255
>=30.0 kg/m^219

9 further baseline measures are reported on the registry.

08

Study locations

30 sites
  • Woodland International research Group
    Little Rock, Arkansas 72211, United States
  • CNRI-Los Angeles, LLC
    Pico Rivera, California 90660, United States
  • UCSD Medical Center UCSD Department of Psychiatry
    San Diego, California 92103-8229, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Kashinath Yadalam
    Lake Charles, Louisiana 70629, United States
  • Pillar Clinical Research, LLC
    Dallas, Texas 75243, United States
  • Bugát Pál Kórház-Rendelőintézet, Rehabilitációs Elmegyógyászati Osztály
    Gyongyos, Dózsa György út 20-22, Hungary
  • Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza, Pszichiatriai Osztaly
    Gyula, 5700, Hungary
  • Spitalul Universitar de Urgenta Militar Central "Dr. Carol Davila"
    Bucuresti, 010825, Romania
  • Centrul de Evaluarea si Tratament al Toxicodependentelor pentru Tineri "Sf. Stelian", Sectia Psihiatrie
    Bucuresti, 060222, Romania
  • spitalul Clinic de Neuropsihiatrie Craiova ,Clinica II Psihiatrie
    Craiova, 200473, Romania
  • Institutul de Psihiatrie Socola Iasi, Sectia Psihiatrie III Acuti
    Iasi, 700282, Romania
  • Sverdlov Regional Psychiatric Clinical Hospital
    Ekaterinburg, 620030, Russian Federation
  • St-Petersburg SHI Psychiatrical hospital #1 n.a. Kaschenko
    Gatchina, 188357, Russian Federation
  • SPHI "City Mental Hospital #3 n.a. I.I.Skvortsov-Stepanov"
    Saint-Petersburg, 197341, Russian Federation
  • SHI Regional Clinical Psychiatry Hospital of St. Sofia
    Saratov, 410060, Russian Federation
  • FSBEI HE "Smolensk State Medical University" of the MoH of the RF
    Smolensk, 214019, Russian Federation
  • City Psychiatric Hospital of St. Nikolay Chudotvorets
    St. Petersburg, 190121, Russian Federation
  • FB=SBI"Saint Petersburg Scientific and Research Psychoneurological Institute n.a. V.M. Bekhterev"
    St. Petersburg, 192019, Russian Federation
  • SPb SBIH "City Psychoneurological Dispensary #7 (with inpatient facilities)"
    St. Petersburg, 198020, Russian Federation
  • Regional Psychoneurological Hospital #3, Dept of Crisis Cond & Primary Psych Episode #1
    Ivano Frankivsk, 76014, Ukraine
  • CHI Kharkiv RCPH#3 Center of Emerg PsychSI Inst of Neur, Psych & Narc of NAMSU, Unit of Emergency Psychiatry and Narcology
    Kharkiv, 61068, Ukraine
  • CHI Kharkiv Regional Clinical Psychiatric Hospital #3, Psychiatric Department of Primary Psychotic Episod
    Kharkiv, 61068, Ukraine
  • CI Kherson Regional Psychiatric Hospital of Kherson RC
    Kherson, 73488, Ukraine
  • TMA Psychiatry in Kyiv Center of NT & Rehabilitation of Psychotic Conditions
    Kyiv, 04080, Ukraine
  • CI Odesa Regional Medical Center of Mental Health
    Odesa, 65006, Ukraine
  • CI Cherkasy Regional Psychiatric Hospital of ChRC, Femail Dept #11, Male Dept #12
    Smila, 20708, Ukraine
  • Ternopil RCCPH Depts of Psychiatry #2 (m) & Psychiatry #6 Ternopil I.ya. Gorbachevskyi SMU
    Ternopil, 46020, Ukraine
  • Transcarpathian Regional Narcological Dispensary
    Uzhgorod, 88000, Ukraine
  • CI O.I. Yuschenko VRPsH Depts #7 & #10 M.I. Pyrogov VNMU
    Vinnytsia, 21005, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Jan 2019, 23 months.

Results were first posted in Feb 2022, 3 years after primary completion. A results delay was requested in Dec 2019.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 23 months is above that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2016
First posted
Nov 22, 2016
StartActual
Jan 31, 2017
Primary completionActual
Jan 29, 2019
CompletionActual
Jan 29, 2019
Results delay requested
Dec 2, 2019
Results first posted
Feb 9, 2022
Last update
Jul 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02970929
Responsible party
Sponsor
First posted
Nov 22, 2016
Start date
Jan 31, 2017
Primary completion
Jan 29, 2019
Completion
Jan 29, 2019
Results posted
Feb 9, 2022
Last update
Jul 5, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SEP-363856

Start the discussion